Sep 8, 2025, 14:24
Von Willebrand Factor as a Therapeutic Target․ From Development to Clinical Application
Thrombosis & Haemostasis Journal (TH Open) shared a post on X.
“Von Willebrand Factor as a Therapeutic Target in Thrombotic Disorders.
Jongejan and colleagues review the evolution of VWF-targeting therapeutic agents, their developmental stages and clinical indications.”
Read full abstract here.
Stay informed with Hemostasis Today.
-
Jul 10, 2026, 20:47New Machine Learning Models Improve Prediction of Thrombosis and Bleeding in Cancer – JTH
-
Jul 10, 2026, 20:39Evangelia Petsalaki: New Systems Biology Approach Identifies Biomarkers in Thrombotic APS
-
Jul 10, 2026, 20:29Wolfgang Miesbach: Celebrating Pantep Angchaisuksiri’s Transformative Leadership of the ISTH
-
Jul 10, 2026, 20:17Amy Pantaleo: How Staffing Shortages Are Changing Hemostasis Laboratories
-
Jul 10, 2026, 20:15Gene Nudelman: Early Hemorrhage Control Improves Patient Outcomes
-
Jul 10, 2026, 20:15Lee G.: Can We Transform Dengue Patient Management with Better Coagulation Assessment?
-
Jul 10, 2026, 20:13Shahin Alam: Is Your Coagulant Limiting Your Water Treatment Performance?
-
Jul 10, 2026, 20:12Ali Bozorgi: Our Meta-Analysis on Oral Anticoagulation After AF Ablation Featured in EP Europace
-
Jul 10, 2026, 15:34Joy Celebre: A New Opportunity in Hemostasis Leadership